ManagedCareEye.com Presents: Managed Care Review Board™ - Assessing Recent Advances for Enhanced Management of Retinal Diseases

Learn About:

• Treatment strategies and resources for achieving the best patient outcomes
• Medical and pharmacy benefit design approaches to streamline patient access
• Pharmacological treatment alternatives for retinal diseases

Expert Faculty Presenters

James Chambers, PhD, MPharm Associate Professor of Medicine Tufts Medical Center Institute for Clinical Research and Health Policy Studies Click here for biography Jordan M. Graff, MD, FACS Surgeon & Partner, BDP Eye Center at American Vision Partners (AVP) Chair, Division of Ophthalmology, Creighton University Clinical Assistant Professor, University of Arizona, Phoenix Medical Executive Committee, AVP - Phoenix, AZ Click here for biography Dana McCormick, RPh, FAMCP Senior Director, Pharmacy Advisory Services Optum Insights Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
Managed care plays a pivotal role in ensuring optimal patient outcomes and cost-effective medication management strategies in retinal disease. Regarding assessing recent treatment advances for retinal diseases, managed care professionals need to stay abreast of emerging treatment modalities and therapeutic breakthroughs. Understanding the mechanisms of action, efficacy profiles, safety considerations, and cost-effectiveness of novel medications and interventions for retinal diseases is crucial to supporting patient adherence to treatment and preventing blindness. Pharmacists should be knowledgeable about the evolving landscape of pharmacotherapy, including anti-vascular endothelial growth factor (anti-VEGF) agents, sustained-release drug delivery systems, and emerging therapies. Leverage the expertise of this interactive multistakeholder panel discussion to optimize treatment outcomes, enhance patient care, and manage health care costs of retinal diseases.

Educational Objectives
After completing this activity, the participant should be better able to:

• Evaluate treatment strategies and resources based on evidence for achieving the best patient outcomes in cases of retinal diseases.
• Describe pharmacological treatment alternatives for retinal diseases, considering their effectiveness, safety, and recommended dosing intervals.
• Assess medical and pharmacy benefit design approaches to streamline patient care to evidence-based treatments for retinal diseases.
• Outline efforts between payers and providers to enhance the treatment of retinal diseases through education and coordination.

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by the Medical Education Resources and Impact Education, LLC. Medical Education Resources is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Education Resources designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA0003680-9999-24-148-L01-P
Activity Type: Knowledge-based

Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources, Inc. to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, Medical Education Resources, Inc. identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Medical Education Resources, Inc. to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

The MER planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.

Please note: Registration for AMCP 2024 is NOT required to attend this symposium.